Human Trials

Xeris Pharmaceuticals doses first patient in phase 2 trial to assess ready-to-use glucagon

Xeris Pharmaceuticals has now begun dosing patients in a phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia (EIH).

Esperion unveils positive human trial results for new cholesterol-lowering drug

Esperion Therapeutics said the phase 3 long-term safety study showed that bempedoic acid has significantly reduced low-density lipoprotein cholesterol (LDL-C), as well as high-sensitivity C-reactive protein (hsCRP).

BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805.

Parkinson’s disease study reveals how cancer drug reduces toxic protein in brain

Researchers at the US-based Georgetown University Medical Center claimed to have understood how a cancer drug functions in the brains of patients with Parkinson’s disease.

Lilly’s CYRAMZA meets primary endpoint in phase 3 RELAY trial

Eli Lilly and Company has announced that its Phase 3 RELAY study of CYRAMZA (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment.

Tenax Therapeutics recruits first patient in phase 2 pulmonary hypertension clinical trial

Tenax Therapeutics announced that the first patient has been randomized for its phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).

Gilead announces data from two studies supporting further development of investigational HIV-1 capsid inhibitor GS-6207

Gilead Sciences has announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy.

ViiV Healthcare reports positive data for two phase 3 HIV trials of cabotegravir, rilpivirine regimen

ViiV Healthcare presented comprehensive 48-week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies of the novel, investigational, long-acting regimen of cabotegravir and rilpivirine.

HIV remission achieved in second patient

A second person has experienced sustained remission from HIV-1 after ceasing treatment, reports a paper led by UCL and Imperial College London.